Synapse Open Synapse
Biology

Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

BioPharma Dive · · 5 min read

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

Latest from BioPharma Dive